Peginterferon alfa-2b

Drug Profile

Peginterferon alfa-2b

Alternative Names: Cylatron; Interferon-alpha-2b macrogol; Intron A Peg; PEG interferon-alpha-2b; PEG-Intron; PEG-Intron A; PEG-Intron-A; Pegatron; PegIntron; Pegintron; Pegtron; Pegylated IFN alfa-2b; Pegylated IFN-alpha 2b; Pegylated interferon-alpha-2b; pIFN - alpha 2b; Polyethylene glycol interferon-alpha-2b; SCH 54031; ViraferonPeg

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Enzon Pharmaceuticals; Merck & Co; Schering-Plough; Wistar Institute
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C; Malignant melanoma
  • Phase II HIV infections
  • Discontinued Chronic myeloid leukaemia; Multiple sclerosis; Polycythaemia vera; Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Merck completes a phase II trial for Malignant melanoma (Adjuvant therapy) in Russia (NCT02155322)
  • 03 Feb 2016 Merck & Co terminates a phase III trial in Hepatitis B in Australia (NCT01641926)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top